Abstract
Slowing of Brain Volume Loss in Patients With Relapsing-Remitting Multiple Sclerosis After Switching From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.264)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have